01 December 2024 : Clinical Research
Rituximab use in Rheumatoid Arthritis: A Seven-Year Retrospective Study of 52 Patients at a Saudi Arabian Hospital
Sumayah Sulaiman Bafana1BCE, Fahidah Alenzi
2EFG*, Ibrahim Almaghlouth1AD, Eman Alqurtas 1AD, Mohammed K. Bedaiwi1ABD, Haya M. M. Almalag 3AD, Mohammed A. Omair 1ACDEF
DOI: 10.12659/MSM.946178
Med Sci Monit 2024; 30:e946178
Table 2 Patients’ medication profiles.
| Pre-rituximab treatment | |
|---|---|
| 0 | 3 (5.77) |
| 1 | 34 (65.38) |
| 2 | 11 (21.15) |
| 3 | 4 (7.69) |
| None | 4 (7.69) |
| Methotrexate monotherapy | 33 (63.46) |
| Methotrexate based combination | 13 (25) |
| Other csDMARDs | 2 (3.85) |
| Prednisolone at RTX initiation (n (%)) | 22 (42.31) |
| Prednisolone dose (mean±SD) | 3.4±5.53 |
| Number of patients on prednisolone at the last encounter (n (%)) | 12 (54.5) |
| Mean prednisolone dose at the last clinic encounter (mean±SD) | 10.90±8.5 |
| csDMARDs – conventional synthetic disease-modifying anti-rheumatic drugs; RTX – rituximab. | |